Sierra Oncology Inc (SRRA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

2150 ? 885 WEST GEORGIA STREET VANCOUVER, BRITISH COLUMBIA, CANADA V6C 3E8

Sierra Oncology, Inc. operates as a clinical-stage oncology company. The Company develops therapies that target deoxyribonucleic acid (DNA) to treat patients with cancers and other complex genetic diseases. Sierra Oncology serves customers in North America.

Data as of 2020-11-22
Market Cap165.609 Million Shares Outstanding11.041 Million Avg 30-day Volume15.159 Thousand
P/E Ratio-1.0 Dividend Yield EPS-14.53
Price/Sales1656.09 Price cash flow ratio Price free cash flow ratio-3.2
Book Value9.54 Price to Tangible Book1.57 Alpha-0.05
Short Interest Ratio % Short Interest to Float R-squared0.071727
BETA1.35736 52-week High/Low22.0 / 8.545 Stddev0.213578
View SEC Filings from SRRA instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 3 2 50.0% 1 (0.07%) 0 (0.0%)
Funds Holding: 27 26 3.85% 13 (0.85%) 11 (0.71%) 18.18%
13F shares: 6.88 Million 6.776 Million 1.54% 5.039 Million 4.573 Million 10.2%
% Ownership 66.1813 65.1779 1.54% 48.4764 43.9915 10.19%
New Positions: 3 6 -50.0% 2 2 0.0%
Increased Positions 6 4 50.0% 2 3 -33.33%
Closed Positions 2 2 0.0% 1
Reduced Positions 4 4 0.0% 2 1 100.0%
Total Calls 0 0
Total Puts 0 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SRRA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SRRA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KLENCKE BARBARA CHIEF DEVELOPMENT OFFICER

  • Officer
15,000 2020-08-18 2

JAGPAL SUKHI CHIEF FINANCIAL OFFICER

  • Officer
0 2020-08-12 2

KOWALSKI MARK CHIEF MEDICAL OFFICER

  • Officer
0 2020-08-12 2

NORRETT KEVIN CHIEF BUSINESS OFFICER

  • Officer
0 2020-08-10 2

TURNER WILLIAM D. CHIEF REG & TECH OPS OFFICER

  • Officer
0 2020-08-04 2

THOMSON CHRISTINA GENERAL COUNSEL

  • Officer
0 2020-07-28 2

PELZER ROBERT

  • Director
0 2020-06-09 1

COOPER JEFFREY H

  • Director
0 2020-06-09 1

ALLEN ANDREW R

  • Director
0 2020-06-09 1

AGGARWAL GAURAV

  • Director
  • 10% Owner
0 2020-06-09 2

ASHIYA MONA

  • Director
  • 10% Owner
0 2020-06-09 2

RICHARDSON JOSHUA

  • Director
  • 10% Owner
0 2020-06-09 2

SINCLAIR ANDREW

  • Director
0 2020-06-09 3

DILLY STEPHEN GEORGE CEO AND PRESIDENT

  • Officer
  • Director
0 2020-06-01 2

COLLARD CRAIG A

  • Director
0 2020-05-28 2

GLOVER NICHOLAS CEO AND PRESIDENT

  • Officer
  • Director
0 2020-02-25 1

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VII LLC

ORBIMED GLOBAL HEALTHCARE GP LLC

ORBIMED CAPITAL LLC

  • Director
  • 10% Owner
1,477,320 2020-01-29 1

LONGITUDE CAPITAL PARTNERS III, LLC

LONGITUDE VENTURE PARTNERS III, L.P.

TAMMENOMS BAKKER JULIET

ENRIGHT PATRICK G

  • 10% Owner
1,477,320 2020-01-29 1

VIVO OPPORTUNITY, LLC

VIVO OPPORTUNITY FUND, L.P.

VIVO CAPITAL IX, LLC

VIVO CAPITAL FUND IX, L.P.

VIVO VENTURES VII, LLC

VIVO VENTURES FUND VII, L.P.

VIVO VENTURES VII AFFILIATES FUND, L.P.

  • 10% Owner
1,917,074 2020-01-29 1

ONETTO NICOLE

  • Director
0 2019-06-11 0

PARFET DONALD R

  • Director
0 2019-06-11 0

NGUYEN TRAN

  • Director
0 2019-06-11 0

ESTES DANIEL

  • Director
0 2019-06-11 0

HASSIG CHRISTIAN CHIEF SCIENTIFIC OFFICER

  • Officer
0 2019-03-04 0

YOU ANGIE CHIEF BUS. & STRAT. OFFICER

  • Officer
0 2018-03-06 0

TOPPER JAMES N

  • Director
  • 10% Owner
8,112,121 2017-02-14 0

FRAZIER HEALTHCARE VI, L.P.

FHM VI, L.P.

FHM VI, L.L.C.

FRAZIER LIFE SCIENCES VIII, L.P.

FHM LIFE SCIENCES VIII, L.P.

FHM LIFE SCIENCES VIII, L.L.C.

FRAZIER ALAN D

NAINI NADER J

EVERY NATHAN R

HERON PATRICK J

  • 10% Owner
8,112,121 2017-02-14 0

CHAPMAN WENDY SVP CLINICAL OPERATIONS

  • Officer
0 2016-03-22 0

LOVEJOY CHANDRA D SVP OF REG. AFFAIRS & QUALITY

  • Officer
0 2016-03-08 0

MESSMANN RICHARD A CHIEF MEDICAL OFFICER

  • Officer
0 2016-03-08 0

RODIGUEZA WENDI CHIEF SCIENTIFIC OFFICER

  • Officer
156,276 2016-01-20 0

ANDERSON KEITH EDWARD SVP, TECHNICAL OPERATIONS

  • Officer
0 2015-12-01 0

CHA ALBERT

  • Director
2,438,270 2015-07-21 0

ORBIMED ADVISORS LLC

ISALY SAMUEL D

ORBIMED PRIVATE INVESTMENTS V, LP

  • Director
1,989,949 2015-07-21 0

THOMPSON PETER A.

  • Director
1,989,949 2015-07-21 0

VITANGCOL ALVIN

  • Director
798,762 2015-07-21 0

VIVO VENTURES VII, LLC

VIVO VENTURES FUND VII, L.P.

VIVO VENTURES VII AFFILIATES FUND, L.P.

  • FORMER 10% HOLDERFORMER 10% HOLDERFORMER 10% HOLDER
No longer subject to file 2015-07-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

**EXPERIMENTAL** Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin
Morgan Stanley Alphamab Oncology - B 2.99% 2020-01-07 Hong Kong

Short Position History

Holder Net Short Position Position Date Origin
Morgan Stanley Alphamab Oncology - B 2.99% 2019-12-23 Hong Kong
Morgan Stanley Alphamab Oncology - B 2.99% 2020-01-03 Hong Kong
Morgan Stanley Alphamab Oncology - B 2.99% 2020-01-04 Hong Kong
Morgan Stanley Alphamab Oncology - B 2.99% 2019-12-19 Hong Kong

Elevate your investments